Life Science Investing Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
Life Science Investing Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
Life Science Investing Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
Life Science Investing Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology Congress
Life Science Investing Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Life Science Investing Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
